Ranbaxy makes $500 million provision related to US settlement

21 Dec 2011 Evaluate

Ranbaxy has agreed to a settlement with the US Food and Drug Administration (USFDA) and will make a $500 million provision in relation to a Department of Justice (DoJ) probe to resolve a dispute about plant violations.

Ranbaxy Laboratories Ltd. has signed a consent decree with the U.S. Food and Drug Administration (FDA). Ranbaxy has committed to further strengthen procedures and policies to ensure data integrity. It has also agreed to comply with current good manufacturing practices. The company says that the consent decree is subject to approval by the US District Court for the District of Maryland.

Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×